GeneHealth - Your precision medicine

Renal Hypomagnesemia 2

Disease Details

Family Health Simplified

Buy Membership

Description: Renal hypomagnesemia 2 is a genetic disorder characterized by difficulty in the kidneys to reabsorb magnesium, leading to low levels of magnesium in the blood.
Type: Renal hypomagnesemia 2 (HOMG2) is transmitted in an autosomal dominant manner.
Signs And Symptoms: Renal hypomagnesemia 2 is a genetic disorder characterized by low levels of magnesium in the blood due to problems with magnesium reabsorption in the kidneys.

Signs and symptoms:
1. Muscle cramps and spasms
2. Weakness and fatigue
3. Seizures
4. Cardiac arrhythmias
5. Nausea and vomiting
6. Tetany (involuntary muscle contractions)
7. Personality changes, including irritability and depression
Prognosis: Renal hypomagnesemia 2, or Renal Hypomagnesemia with Secondary Hypocalcemia (HOMG2), is a rare genetic disorder that leads to excessive loss of magnesium in the urine, resulting in low blood magnesium levels and secondary hypocalcemia. The prognosis can vary depending on the severity of the condition and the effectiveness of treatment.

Prognosis:
- With proper management, which includes magnesium supplementation to maintain normal blood magnesium levels, many patients can lead relatively normal lives.
- However, if untreated, the condition can lead to complications such as seizures, muscle spasms, and other neuromuscular symptoms due to low magnesium and calcium levels.
- Early diagnosis and consistent treatment are key to improving health outcomes and quality of life.

There is no information provided for "nan." If you meant something else, please clarify.
Onset: Renal hypomagnesemia 2 is a disorder characterized by the body's inability to properly reabsorb magnesium in the kidneys, leading to low levels of magnesium in the blood. The onset of this condition can vary, but it often presents in childhood or adolescence with symptoms such as muscle cramps, seizures, and cardiac arrhythmias.
Prevalence: The prevalence of renal hypomagnesemia 2 is not well-defined in the medical literature due to its rarity. It is considered a rare genetic disorder with limited reported cases.
Epidemiology: Renal hypomagnesemia 2 is an extremely rare genetic disorder characterized by impaired reabsorption of magnesium in the kidneys, leading to excessive loss of magnesium in the urine. Epidemiological data specifically for renal hypomagnesemia 2 are limited due to its rarity. It is often identified in individuals with a family history of the condition or through genetic testing following the presentation of symptoms such as muscle cramps, seizures, or arrhythmias related to low magnesium levels.
Intractability: Renal hypomagnesemia 2, also known as familial hypomagnesemia with secondary hypocalcemia (HSH), is generally considered a manageable condition rather than intractable. Treatment typically involves magnesium supplementation to maintain appropriate serum magnesium levels and manage symptoms. However, the condition requires ongoing management and monitoring to prevent complications.
Disease Severity: Renal hypomagnesemia 2, or Familial Hypomagnesemia with Hypercalciuria and Nephrocalcinosis (FHHNC), is generally a severe condition. It is characterized by early-onset hypomagnesemia (low magnesium levels in the blood), hypercalciuria (high calcium levels in the urine), and nephrocalcinosis (calcium deposits in the kidneys), leading to progressively declining kidney function and ultimately to renal failure if untreated.
Healthcare Professionals: Disease Ontology ID - DOID:0060885
Pathophysiology: Renal hypomagnesemia 2, known as Familial Hypomagnesemia with Hypercalciuria and Nephrocalcinosis (FHHNC), is a genetic disorder characterized by impaired reabsorption of magnesium and calcium in the kidneys. The condition is primarily caused by mutations in the **CLDN16** or **CLDN19** genes, which encode claudin-16 and claudin-19 proteins, respectively. These proteins are crucial components of tight junctions in the renal tubules, particularly in the thick ascending limb of the loop of Henle.

In healthy kidneys, claudin-16 and claudin-19 facilitate the paracellular reabsorption of magnesium and calcium. Mutations in these genes disrupt this process, leading to excessive excretion of magnesium (hypomagnesemia) and calcium (hypercalciuria) in the urine. Over time, the imbalance can result in nephrocalcinosis, where calcium deposits form in the kidney tissues. This condition often leads to progressive kidney damage and can result in chronic kidney disease or renal failure.
Carrier Status: Renal hypomagnesemia 2 (HOMG2) is an autosomal recessive disorder. Carrier status would imply that an individual has one copy of the mutated gene but typically does not show symptoms.
Mechanism: Renal hypomagnesemia 2, also known as Familial Hypomagnesemia with Hypercalciuria and Nephrocalcinosis (FHHNC) type 2, involves a defect in the reabsorption of magnesium in the renal tubules.

**Mechanism:**
This condition is characterized by excessive loss of magnesium in the urine due to impaired tubular reabsorption in the kidneys. This results in low magnesium levels in the blood (hypomagnesemia), high levels of calcium in urine (hypercalciuria), and the deposition of calcium in the kidneys (nephrocalcinosis).

**Molecular Mechanisms:**
1. **Mutations in the genes:**
The primary molecular defect in Renal Hypomagnesemia 2 involves mutations in genes encoding for proteins essential for magnesium reabsorption in the thick ascending limb (TAL) of the Loop of Henle. The two key genes implicated are:
- **CLDN16 (claudin-16):** Encodes a tight junction protein critical for paracellular magnesium reabsorption.
- **CLDN19 (claudin-19):** Also encodes a tight junction protein that is crucial for the same pathway and affects both magnesium and calcium reabsorption.

2. **Effects of Mutations:**
- **Disruption of Tight Junctions:** Mutations in CLDN16 or CLDN19 lead to dysfunctional tight junctions, hindering the paracellular pathway that normally allows magnesium to be reabsorbed from the filtrate back into the blood.
- **Loss of Electrochemical Gradient:** Proper function of claudin-16 and claudin-19 is necessary to maintain the electrochemical gradient that drives magnesium reabsorption. Mutations can disrupt this gradient, further impairing magnesium uptake.

These genetic abnormalities ultimately lead to a reduced ability of the kidneys to reabsorb magnesium, causing the symptoms associated with Renal Hypomagnesemia 2.
Treatment: Renal hypomagnesemia 2, also known as familial hypomagnesemia with secondary hypocalcemia, is typically treated with oral magnesium supplementation. In severe cases, intravenous magnesium may be required. Patients often need lifelong magnesium replacement therapy. Additionally, managing blood calcium levels may also be necessary to address secondary hypocalcemia.
Compassionate Use Treatment: For renal hypomagnesemia type 2, there are no widely established compassionate use treatments. However, several off-label and experimental treatments may be considered:

1. **Magnesium Supplements**: Oral magnesium supplements can help increase serum magnesium levels, although their efficacy varies among patients.

2. **Thiazide Diuretics**: These are sometimes used off-label to reduce urinary magnesium loss. They work by reducing the renal excretion of magnesium.

3. **Investigational Therapies**: Research into new therapeutic agents that target specific pathways involved in renal magnesium handling is ongoing, although these are not yet widely available for clinical use.

Patients should consult with their healthcare providers to discuss potential treatment options and the risks and benefits associated with them.
Lifestyle Recommendations: For Renal Hypomagnesemia Type 2, here are some lifestyle recommendations:

1. **Dietary Adjustments**:
- Increase intake of magnesium-rich foods, such as nuts, seeds, whole grains, green leafy vegetables, and legumes.
- Consider magnesium supplements if recommended by a healthcare provider.

2. **Hydration**:
- Maintain adequate hydration to support renal function.

3. **Medication Review**:
- Consult with a healthcare provider about any medications that may affect magnesium levels. Some diuretics and antibiotics can deplete magnesium.

4. **Regular Monitoring**:
- Regular blood tests to monitor magnesium levels and kidney function.

5. **Avoid Excessive Alcohol**:
- Limit alcohol consumption as it can interfere with magnesium absorption and excretion.

6. **Stress Management**:
- Practice stress-relieving activities such as yoga, meditation, or gentle exercise, as stress can affect overall health.

7. **Follow-up Care**:
- Regular follow-up with a healthcare provider, preferably a nephrologist or a specialist managing kidney diseases.

These recommendations should be personalized based on individual health conditions and professional medical advice.
Medication: Renal hypomagnesemia 2, also known as familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC), generally focuses on managing magnesium levels and preventing complications. Key treatment options may include:

1. **Oral Magnesium Supplements:** To increase magnesium levels in the blood.
2. **Thiazide Diuretics:** These may be used to reduce urinary calcium excretion.
3. **Hydration:** Increased fluid intake to prevent nephrocalcinosis and kidney stones.

Specific medication recommendations should be determined by a healthcare provider based on individual patient needs.
Repurposable Drugs: Renal hypomagnesemia type 2, also known as familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC), is a rare genetic disorder affecting the kidneys' ability to reabsorb magnesium. Currently, there are no widely recognized repurposable drugs specifically for this condition. Management typically involves magnesium supplementation to address the deficiency and careful monitoring of kidney function. It is advisable to consult a medical professional for personalized treatment options.
Metabolites: Renal hypomagnesemia type 2 (or familial hypomagnesemia with secondary hypocalcemia, HSH) typically involves abnormalities in magnesium reabsorption in the kidney, leading to low magnesium levels in the blood. Relevant metabolites primarily include:

1. Magnesium: Significantly decreased in blood levels.
2. Calcium: Often decreased due to secondary hypocalcemia, resulting from low magnesium.
3. Parathyroid hormone (PTH): Can be variably affected due to disrupted magnesium homeostasis, potentially leading to parathyroid function abnormalities.
4. Creatinine: May be monitored to assess kidney function but is not directly altered by the disease in early stages.

These metabolites are key in diagnosing and monitoring renal hypomagnesemia type 2.
Nutraceuticals: For renal hypomagnesemia 2, there is currently no specific nutraceutical known to effectively manage this condition. Treatment primarily focuses on magnesium supplementation, either orally or intravenously, to address the magnesium deficiency. It is crucial for patients to be under medical supervision for appropriate diagnosis, monitoring, and management.
Peptides: Renal hypomagnesemia type 2 (HOMG2) is primarily associated with mutations in the gene encoding the tight junction protein claudin-16 (CLDN16). This condition results in impaired reabsorption of magnesium in the kidney. Research into therapeutic peptides or nanotechnology-based treatments for this specific condition is currently limited, with primary management typically focusing on magnesium supplementation and monitoring.